Please ensure Javascript is enabled for purposes of website accessibility

Profits Dive 31% at AstraZeneca

By Mark Rogers - Apr 25, 2013 at 1:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

AstraZeneca issues its first-quarter results.

LONDON -- Shares of AstraZeneca (AZN -2.33%) (AZN -3.53%) dropped 1% to 3,353 pence during early London trade this morning after the FTSE 100 member reported first-quarter sales falling 13% to $6.4 billion.

AstraZeneca, the world's fifth-largest pharmaceutical group, revealed profits for the quarter had declined 31% to $1 billion, compared to $1.6 billion last year. Core operating margins fell from 40.8% to 36.4%.

The company confirmed that the "key drivers" for the revenue shortfall were anticipated expiry of patents and the loss of exclusivity in certain markets of major anti-psychotic and heart medicines. While emerging-market revenues increased by 9%, this performance was more than offset by U.S. and European sales falling 16%.

Looking ahead, AstraZeneca revealed it expected group profits to "decline at a rate that is significantly higher than the decline in revenue in 2013," while maintaining current sales expectations.

Chief executive Pascal Soriot commented:

As anticipated, the first quarter performance reflects the loss of exclusivity for several large products. We remain focused on our strategic priorities of returning to growth and achieving scientific leadership."

"Brilinta, the diabetes franchise, Emerging Markets, Japan and our Respiratory products have all made good progress and we continued to invest in distinctive science that will advance our knowledge of disease physiology and help to identify new drug targets.

The company will hold its annual general meeting later today, where shareholders are expected to vote on Soriot's $11 million pay package.

With a market cap of 42 billion pounds, AstraZeneca is valued at around 9.8 times expected earnings and offers an impressive prospective dividend yield of 5.5%.

While that yield might appear attractive, there aren't many global companies whose dividend can match the long-term stability or visibility laid out by "The Motley Fool's Top Income Stock for 2013."

In fact, the Fool's choice recently revealed its dividend would increase at least in line with the rate of U.K. inflation for the foreseeable future and provides a market-beating 5.1% yield.

Just click here to download the free exclusive report.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$10,244.00 (-2.33%) $-244.00
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$63.32 (-3.53%) $-2.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.